Kevin HernSell
OGN · Transaction Aug 5, 2026 · Filed Aug 12, 2026 · $1,001 to $15,000
XNYS · OGN
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Organon & Co.
PHARMACEUTICAL PREPARATIONS
$13.68
Veridion Score
BETAHIGH CONF · 6/6 factorsTue Aug 18 · last completed session · Pre-market · regular session opens 9:30 ET · OGN
MethodologyOGN
Organon & Co.
Tue Aug 18 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
46/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Tue Aug 18 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is OGN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Organon & Co.
PHARMACEUTICAL PREPARATIONSListed since
2021
Employees
10K
Country
US
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$13.68
Last session
Day high
$13.68
Last session
Day low
$13.68
Last session
Previous close
$13.68
52W high
$13.72
-0.29% from high
52W low
$5.70
100% of range
Market cap
$3.6B
P/E
6.45×
EPS
$2.12
Beta
0.67
Shares out
262.6M
Avg volume
2.5M
VWAP
$13.68
Last session
Price history computed in-house
1W
+0.15%
1M
+1.41%
3M
+1.94%
1Y
+47.73%
YTD
+90.79%
SMA 50 $13.52 · above
SMA 200 $9.85 · above
52W position 100%
OGN overview
Related filings and maps
Public disclosures
Congress activity in OGN
Official filing ↗
Organon & Co. Common Stock · Transaction Aug 5, 2026 · Filed Aug 10, 2026 · $1,001 to $15,000
Organon & Co. · Transaction Jul 10, 2025 · Filed Nov 24, 2025 · $1,001 to $15,000
Ro KhannaSell
OGN Common Stock · Transaction Dec 4, 2023 · Filed Jan 4, 2024 · Amount pending receipt enrichment
Ro KhannaSell
OGN Common Stock · Transaction Nov 3, 2023 · Filed Dec 6, 2023 · Amount pending receipt enrichment
Federal contracts
OGN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for OGN in this window.
Lobbying spend
OGN lobbying filings, year to date.
Registered lobbying filings matched to Organon & Co..
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for OGN in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for OGN.
Options
Sovereign unlock shows live options positioning for OGN.